Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo is a research paper published in Nucleic Acids Research (2020). On theSindex it has a DataRank of 0. It has been cited 90 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: R01CA226852
National Cancer Institute
Grant: R01CA158073
National Cancer Institute
Grant: R01CA215067
National Cancer Institute
Grant: P01CA174653
Canadian Institute of Health Research
Grant: BMA342854
NCI
Grant: P30CA013696
National Institutes of Health
Grant: 3P30CA013696-21S1
CANCER CENTER CORE SUPPORT GRANT
National Institutes of Health
Grant: 5P01CA174653-02
Molecular Mechanisms of Initiation of Double-Strand Break Repair
National Institutes of Health
Grant: 5R01CA226852-02
The catalytic and non-catalytic functions of PARP1 in cancer biology
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 5R01CA158073-05
The Role of ATM in Suppression of Lymphomas
National Institutes of Health
Grant: 5R01CA215067-05
The structural function of ATR in development, oncogenesis and cancer therapy
National Institutes of Health
NIH
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals